Advanced Medical Solutions Grp PLC AMS announces US approval for LiquiBand(R) XL (6669M)
25 Maio 2022 - 3:00AM
UK Regulatory
TIDMAMS
RNS Number : 6669M
Advanced Medical Solutions Grp PLC
25 May 2022
25 May 2022
Advanced Medical Solutions Group plc
("AMS" or the "Group")
US regulatory approval for LiquiBand(R) XL
Winsford, UK : Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies, is
pleased to announce that it has received FDA 510(k) approval for
LiquiBand(R) XL, a new device that can close longer wounds than
existing LiquiBand(R) products. The device consists of a surgical
mesh which is used to close the wound and LiquiBand(R) glue which
is used to strengthen the closure and prevent infection. Product
launch into the US is expected in the third quarter of 2022.
The device has been used successfully on a variety of
orthopaedic procedures in multiple territories since its European
approval in 2021 and has received very positive feedback in terms
ease of use, efficacy and reduced pain and scarring in comparison
with other closure methods such as stapling.
The addition of LiquiBand(R) XL to AMS' Advanced Wound Closure
portfolio is an important step in the development of this
franchise. It provides access to a new $60m, long wound sealant
market in the US but also increases the overall strength of the
LiquiBand(R) portfolio, as it completes the range of applications
available, significantly improving the company's ability to win new
contracts and bundle products.
Chris Meredith, Chief Executive Officer of AMS, commented : "I
am delighted to announce the FDA approval of LiquiBand(R) XL in the
US and the addition of this product to our highly successful US
LiquiBand(R) franchise. There is strong demand for the product from
hospitals and our distribution partners and we are confident that
it will make a significant impact in the market and will play a
critical role in strengthening the market share of the entire
LiquiBand(R) franchise."
- End -
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal/ Matthew
Cole
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence
HSBC Bank PLC (Broker) Tel: +44 (0) 20 7991
8888
Sam McLennan / Joe Weaving / Stephanie
Cornish
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative tissue-healing technology, focused on quality outcomes
for patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a
patent-protected sealant technology platform; Biomatlante, an
established French developer and manufacturer of innovative
surgical biomaterial technologies, Raleigh, a UK leading coater and
converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, a specialist distributor
of minimally invasive surgical devices based in Austria.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has more than 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
REASEAFMLEESEFI
(END) Dow Jones Newswires
May 25, 2022 02:00 ET (06:00 GMT)
Advanced Medical Solutions (AQSE:AMS.GB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Advanced Medical Solutions (AQSE:AMS.GB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024